Charles River Laboratories Intl. Inc vs NextEra Energy, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $302.01 (market cap $14.23B), while NextEra Energy, Inc. trades at $76.97 (market cap $161.39B). The key difference: NextEra Energy, Inc. is far larger — about 11.3× Charles River Laboratories Intl. Inc's market cap, and NextEra Energy, Inc. pays a 3.22% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and NextEra Energy, Inc. for 83 Days on average.
| CRL | NEE | |
|---|---|---|
Market Cap | $14.23B | $161.39B |
Volume | 1,176,885 | 11,780,955 |
Sector | Health | Utilities |
52-Week High | $310.77 | $97.88 |
52-Week Low | $149.93 | $75.49 |
Typical Hold Time | 33 Days | 83 Days |
Enterprise Value | $17.06B | $268.72B |
Dividend Yield | — | 3.22% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
NextEra Energy (NEE) trades at $77.06, down 1.05% today, near its 52-week low of $74.78. The stock shows mixed signals with a bearish technical outlook but strong fundamentals, including a 32.4% net income margin and recent earnings beats. Recent news highlights growth initiatives like the Project Star energy infrastructure partnership and a dividend of $0.62 payable in September 2026.
NEE offers a compelling valuation with a P/E of 17.39 and a consensus price target of $96, implying 25% upside. Risks include high debt levels and interest rate sensitivity, but analyst sentiment remains bullish with 66.7% buy ratings. The stock is positioned for long-term growth in clean energy, though near-term volatility may persist.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →